Drug interactions
Dasatinib + Encorafenib
Severity: Major
Dasatinib and Encorafenib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Both drugs can prolong the QT interval, and encorafenib is dose-dependently associated with QT prolongation. Combined use may increase arrhythmia risk, and encorafenib is also a CYP3A4 inducer in some settings.
What this interaction means in plain words
Dasatinib and Encorafenib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Dasatinib belongs to Oncology; Encorafenib belongs to Oncology.
Why it happens
Additive QT prolongation; encorafenib may also induce CYP3A4 and lower dasatinib exposure.
What to do
Avoid the pairing where an alternative exists. If it is used, obtain a baseline ECG and electrolytes and monitor the QTc, interrupting or reducing therapy if it becomes markedly prolonged.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Dasatinib and Encorafenib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Dasatinib
- Dasatinib + Saquinavir Contraindicated
- Dasatinib + Thioridazine Contraindicated
- Adagrasib + Dasatinib Major
- Amiodarone + Dasatinib Major
- Amisulpride + Dasatinib Major
- Amitriptyline + Dasatinib Major
Other interactions of Encorafenib
Frequently asked questions
Can I take Dasatinib with Encorafenib?
MediHelp rates the interaction as major. Dasatinib and Encorafenib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Both drugs can prolong the QT interval, and encorafenib is dose-dependently associated with QT prolongation. Combined use may increase arrhythmia risk, and encorafenib is also a CYP3A4 inducer in some settings.
How serious is the interaction between Dasatinib and Encorafenib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the pairing where an alternative exists. If it is used, obtain a baseline ECG and electrolytes and monitor the QTc, interrupting or reducing therapy if it becomes markedly prolonged.
What other medicines interact with Dasatinib?
MediHelp also lists interactions of Dasatinib with, for example, Saquinavir, Thioridazine, Adagrasib. The full list is on the Dasatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
